Prosecution Insights
Last updated: November 04, 2026
Application No. 18/569,467

USE OF ESSENTIAL OILS AS BIOSTIMULANTS FOR MYCELIA AND MUSHROOMS

Final Rejection §103§112
Filed
Dec 12, 2023
Priority
Jun 17, 2021 — FR FR2106414 +2 more
Examiner
ZHANG SPIERING, DONGXIU
Art Unit
1616
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Myceliance
OA Round
2 (Final)
40%
Grant Probability
Moderate
3-4
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
14 granted / 35 resolved
-20.0% vs TC avg
Strong +66% interview lift
Without
With
+65.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
54 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
43.3%
+3.3% vs TC avg
§102
13.3%
-26.7% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 35 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Amendment filed on 06/16/2026 is acknowledged. Claims 5-12 remain withdrawn with traverse for being drawn to non-elected groups. Claims 1-2 and 4 are amended. Claims 1-4 are pending and being examined on the merits herein. Priority The instant application 18569467, is a 371 of PCT/EP2022/066214, filed on 06/14/2022, which claims foreign priority of France FR2106414, filed on 06/17/2021. Withdrawn Objections/Rejections All previous claim Objection(s) / Rejection(s) as set forth in the previous Office action (mailed 03/16/2026) that are not repeated and/or maintained in the instant Office action are withdrawn, in light of applicant’s amendment and remark filed on 06/16/2026. Claim Objections Claims 1 and 3 are objected to because of the following informalities: Claim 1 needs a period at the end of the claim. Claim 1 recites “beta-pinene, delta-3-carene, or beta-phellandrene, or one of the mixtures thereof”. It is suggested to amend to “beta-pinene, delta-3-carene, beta-phellandrene, and mixtures thereof” to remove the redundant “or” and make the alternative options more presentable. Claim 3 needs to remove a period at the end of the claim due to duplicate periods. Claim 3 recites “beta-pinene, delta-3-carene or beta-phellandrene, or one of the mixtures thereof”. It is suggested to amend to “beta-pinene, delta-3-carene, beta-phellandrene, and mixtures thereof” to remove the redundant “or” and make the alternative options more presentable. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites “wherein the mycelium or mushroom basidiomycetes selected from …”. There is insufficient antecedent basis for this limitation in the claim, because claims 1 or 3, which claim 4 depends upon, both recite “mushroom”, which is not synonymous to “mushroom basidiomycetes”. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1 and 3-4 are rejected under 35 U.S.C. 103 as being unpatentable over Xie et al. (CN109392584, 03/01/2019, machine translation relied upon below; copy attached, PTO-892), in view of Sokovic et al. (European Journal of Plant Pathology; 09/14/2006, IDS of 01/05/2024). Xie throughout the reference directs to interplanting anise with shiitake mushrooms which belongs to Lentinus edodes (e.g., Abstract; [0005]). Regarding instant claims 1 and 3-4, Xie teaches a method for effectively improving quality of growing mushrooms such as shiitake [0027], belonging to Trichlomataceae, Lentinus edodes (e.g., [0005]) (corresponding to instant claim 4) or Ganoderma lucidum, comprising an insect repellent comprising ailanthus leaf extract is rich in terpenes and chrysanthemum leaf extract containing essential oil (e.g., [0027]) by spraying liquid fertilizer and insect repellent comprising the ailanthus leaf extract and chrysanthemum leaf extract once mushroom buds appear (thus providing direct contact to the mycelium or the mushroom) (e.g., [0036]) (corresponding to instant claims 1 and 3). Being Basidiomycetes of shiitake mushroom is the property of shiitake, which has been taught by prior art, therefore, such property would necessarily present in prior art. Moreover, MPEP 2145 II. states that “prima facie obviousness is not rebutted by merely recognizing additional advantages or latent properties present but not recognized in the prior art”, see In re Baxter Travenol Labs., 952 F.2d 388, 21 USPQ2d 1281 (Fed. Cir. 1991). Xie does not teach the chemotyped essential oil species as recited in instant claim 1. Sokovic throughout the reference teaches essential oils having antimicrobial activity against three major pathogens of the button mushroom, Agaricus bisporus (e.g., Abstract). Sokovic teaches that chemotyped essential oils including beta-pinene (Citrus limon % as 17.25%), delta-3-carene and many others have antimicrobial activity against button mushroom Agaricus bisporus pathogens, Verticillium fungicola, Trichoderma harzianum and Pseudomonas tolaasii (e.g., Abstract; Pg. 215, Table 1), and teaches that Pseudomonas tolaasii causes bacterial blotch in button mushroom, as well as shiitake and oyster mushroom (Pg. 212, left top). Sokovic teaches that solutions and emulsions used in the form of sprays with or without a carrier therefore represent the preferred form in which those compounds should be applied to large areas of casing soil surface with minimal effort. Also evaporation by heating could be considered. Further, Oregano oil seems suited to prevent bacterial growth during cultivation and after harvesting (Pg. 223, left Col., 3rd paragraph), implying the compounds being in contact with the mushrooms via spray. It would be prima facie obvious for a person with ordinary skills in the art to combine the teaching of Xie and Sokovic to arrive at current invention. Because Xie teaches terpenes and essential oils from the plant extracts can be insect repellents for improving mushroom quality during the mushroom growth, while Sokovic demonstrates that beta-pinene or delta-3-carene, as specific terpenes, and other essential oils can help control common mushroom pathogens, it would have motivated artisans in the field to select these specific chemotyped essential oils for mushroom growth and would have provided reasonable expectation of success. MPEP 2144.06.I states, "[i]t is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). Regarding “for stimulating the development and growth of a mycelium or of a mushroom” in instant claims 1 and 3, in light of claim interpretation, it is interpreted as intended use of the method. Because Xie and Sokovic teaches the same method comprising contacting the mycelium or mushroom with at least beta-pinene, the intended use would necessarily capable of being achieved. Further, regarding the chemotyped essential oil in instant claim 1, because beta-pinene or delta-3-carene is the same compound as recited in instant claim, the “chemotyped” is inherent property of the essential oil compound, which is already taught by prior art. MPEP 2112.01.II states "[p]roducts of identical chemical composition cannot have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable, as indicated in MPEP 2112.01.II. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id. Claim 2 is rejected under 35 U.S.C. 103 as being unpatentable over Xie et al. (CN109392584, 03/01/2019, machine translation relied upon below; copy attached, PTO-892), in view of Sokovic et al. (European Journal of Plant Pathology; 09/14/2006, IDS of 01/05/2024), as applied to claims 1 and 3-4 above, further in view of Hajdari et al. (SpringerPlus, 2015, PTO-892). Xie and Sokovic teaches a method for growing mushroom with improved quality comprising contacting, e.g., spraying, the mushroom or the mycelium with terpene, e.g., beta-pinene, delta-3-carene, chemotyped essential oil, as applied to claims 1 and 3-4 above in detail, and incorporated herein. The combination of Xie and Sokovic does not teach the essential oil comes from the plants recited in instant claim 2. Hajdari teaches that Pinus mugo Turra, a native pine species in central and southern Europe, yields beta-pinene, delta-3-carene, beta-phellandrene, and other essential oils with great details of essential oil amount information (e.g., Abstract )(corresponding to Pinus mugo in instant claim 2). It would be prima facie obvious for a person with ordinary skills in the art prior to filing date to incorporate Hajdari’s teaching of Pinus mugo as the source of the specific chemotyped essential oils into the method taught by Xie and Sokovic to arrive at current invention. It is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use (MPEP §2144.07). See Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). Response to Arguments Applicant’s remarks/arguments filed on 06/16/2026 have been fully considered. 35 USC 112 Rejections Applicant submits that all claim objections are overcome with the claim amendment. Please note that 35 USC 112 are claim rejections, not claim objections. In light of claim amendment, part of previous 112 rejections are overcome. However, a new rejection arises from claim amendments. Please find the details above in this office action. Art Rejections Applicant asserts that current invention addresses fundamentally different technical problems as stimulating growth and development of mycelium or mushroom, than the cited references of Xie as biocontrol for phytosanitary and protecting crop from pests or diseases while Sokovic essential oils function as antimicrobial or biocidal. A person with ordinary skill in the art would not be motivated to look to references teaching how to repel insects or kill microbes when seeking to stimulate and accelerate growth of mushrooms. The instantly claimed method uses chemotyped essential oils to contact the mycelium or mushroom for stimulating its development and growth, there are no other fundamental method steps in addition to the simple “contacting the mycelium or mushroom” with the essential oils. That being said, prior art teaches this method step as presented in office action in detail. As interpreted in office action, the phrase “for stimulating the development and growth and growth” as the intended use, because it does not contribute to the method steps, therefore, as far as prior art teaches the fundamental step of the method, e.g., contacting the mycelia or mushroom with the essential oils, the intended use, its function, purpose or outcome, would necessarily present in prior art or capable of being achieved. In addition, MPEP 2112.01.II states "[p]roducts of identical chemical composition cannot have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable, as indicated in MPEP 2112.01.II. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id. (Applicant argued that the claimed composition was a pressure sensitive adhesive containing a tacky polymer while the product of the reference was hard and abrasion resistant. "The Board correctly found that the virtual identity of monomers and procedures sufficed to support a prima facie case of unpatentability of Spada’s polymer latexes for lack of novelty."). When essential oil, such as beta-pinene, have been taught by prior art used for contacting mushroom or mycelia, even if the purpose of prior art method is for biocontrol or pest control, the identical chemical compound (e.g., beta-pinene) would necessarily constitute the same property when being in contact with mycelium or mushroom, as instantly claimed, and therefore, it would necessarily carry out stimulating the development and growth of mycelium and mushroom. Furthermore, abiotic stress and biotic stress are known factors impacting crop development and growth. Biotic stress, which is directly related to pest biocontrol, obviously affect crop development and growth in great deal as artisans know in the field. The method to use for pest biocontrol overlaps with the method for protecting crop development and growth, which also results in stimulation of crop development and growth. Moreover, in response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., biostimulant, to stimulate and accelerate the growth) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Note: MPEP 2144. "The reason or motivation to modify the reference may often suggest what the inventor has done but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant". As presented in office action, because Xie teaches terpenes and essential oils from the plant extracts can be insect repellents for improving mushroom quality during the mushroom growth, while Sokovic demonstrates that beta-pinene or delta-3-carene, as specific terpenes, and other essential oils can help control common mushroom pathogens, it would have motivated artisans in the field to select these specific chemotyped essential oils for application to mushrooms and would have provided reasonable expectation of success. Applicant asserts that “chemotyped” essential oil, e.g., beta-pinene, delta-3-carene, or beta-phellandrene, is one in which a specific component is the major constituent, generally present in a proportion greater than 20% (instant Specification); prior art does not teach such chemotyped features. In response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., chemotyped essential oil generally present in a proportion greater than 20%) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Prior art teaches the chemotyped essential oils, e.g., beta-pinene, the proportion greater than 20% in general is not claimed feature. Furthermore, the instant specification is written more in exemplary language (e.g., “generally”) rather than a set definition, and therefore, the proportion greater than 20% is not required limitation. Applicant asserts that there would have no reasonable expectation of achieving a growth-stimulating effect since the references teach using terpenes for antimicrobial or repellent properties, as evidenced by unpredictable activities of these compounds, such as beta-pinene has biostimulant effect while alpha-pinene has inhibitory effect in instant specification. As discussed above, biocontrol for mycelium and mushroom development and growth results in the development and growth of mycelium and mushroom, and in turn, also results in stimulating the development and growth. Furthermore, prior art teaches the same compound beta-pinene as instantly claimed, contacting mycelium and mushroom, exactly as the same claimed method step, the intended use or outcome of the identical method would be obviously present or be capable of being achieved, that is, stimulating mycelium and mushroom development and growth, absent evidence to the contrary. The combination of references is not directed to applying alpha-pinene. In conclusion, applicant’s remarks/arguments are not persuasive. Rejections are remained with updates in light of claim amendments. Please refer to the entire office action as a complete response to the remarks/arguments. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DONGXIU ZHANG SPIERING whose telephone number is (703)756-4796. The examiner can normally be reached 7:30am-5:00pm (Except for Fridays). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SUE X. LIU can be reached at (571)272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DX.Z./ Examiner, Art Unit 1616 /MONICA A SHIN/ Primary Examiner, Art Unit 1616
Read full office action

Prosecution Timeline

Dec 12, 2023
Application Filed
Mar 04, 2026
Response after Non-Final Action
Mar 16, 2026
Non-Final Rejection mailed — §103, §112
Jun 16, 2026
Response Filed
Aug 25, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778867
FATTY ACID MAGNESIUM SALT PARTICLES AND COSMETIC
3y 8m to grant Granted Nov 03, 2026
Patent 12778870
SYNERGISTIC ANTIOXIDANT COMPOSITIONS
3y 5m to grant Granted Nov 03, 2026
Patent 12673138
COMPOSITIONS, APPARATUSES AND METHODS FOR MAKING AND USING BIOSCAFFOLDS
3y 4m to grant Granted Jul 07, 2026
Patent 12662480
MICROBIOCIDAL DERIVATIVES
3y 6m to grant Granted Jun 23, 2026
Patent 12636237
PROCESS FOR MAKING SANITIZING LOTION THAT CAN BE USED AS A MOISTURIZER, MAKEUP REMOVER AND OTHER USES
3y 0m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
40%
Grant Probability
99%
With Interview (+65.9%)
3y 4m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 35 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month